Movement Alert｜Caris Life Sciences, Inc. Rises 5.11% in Regular Trading, BofA Lifts Price Target to 35 USD

Market Focus10-16

On October 16, Caris Life Sciences, Inc. rose 5.11% in Regular Trading, trading at $31.76 per share, with turnover of $67.13 million.

The move appears tied to an event-driven catalyst after BofA Securities raised its price target on the company to $35 from $23, a level above the broader analyst average target of $27.08, improving near-term market sentiment toward the stock.

The rating-related boost was reinforced by recent operating results. Caris Life Sciences, Inc. reported second-quarter revenue of $263.712 million, above the $238.125 million estimate. Earlier, first-quarter revenue reached $216.2 million, up 79% year over year, with EPS at breakeven versus expectations for a small loss, while full-year revenue guidance of $1.0 billion to $1.02 billion was maintained. Together, those figures strengthened the case for valuation re-rating ahead of the next earnings report on November 4.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment